Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors

被引:16
作者
Oh, M
Im, I
Lee, YJ
Kim, YH
Yoon, JH
Park, HG
Higashiyama, S
Kim, YC
Park, WJ
机构
[1] Gwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Kwangju 500712, South Korea
[2] Gwangju Inst Sci & Technol, Natl Res Lab Proteolysis, Buk Gu, Kwangju 500712, South Korea
[3] IDRTech Inc, Gyounggido 463805, South Korea
[4] Pusan Natl Univ, Res Inst Genet Engn, Pusan 609735, South Korea
[5] Ehime Univ, Sch Med, Dept Mol & Cellular Biol, Ehime 7910295, Japan
关键词
ADAM12; inhibitors; virtual screening;
D O I
10.1016/j.bmcl.2004.09.082
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We describe a series of potent and selective inhibitors of ADAM 12 that were discovered using computational screening of a focused virtual library. The initial structure-based virtual screening selected 64 compounds from a 3D database of 67,062 molecules. Being evaluated by a cell-based ADAM12 activity assay, compounds 5, 11, 14, 16 were further identified as the potent and selective inhibitors of ADAM 12 with low nanomolar IC50 values. The mechanism underlying the potency and selectivity of a representative compound. 5, was investigated through molecular docking studies. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6071 / 6074
页数:4
相关论文
共 13 条
[1]  
*ACC INC, INSIGHT2000
[2]   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].
Asakura, M ;
Kitakaze, M ;
Takashima, S ;
Liao, Y ;
Ishikura, F ;
Yoshinaka, T ;
Ohmoto, H ;
Node, K ;
Yoshino, K ;
Ishiguro, H ;
Asanuma, H ;
Sanada, S ;
Matsumura, Y ;
Takeda, H ;
Beppu, S ;
Tada, M ;
Hori, M ;
Higashiyama, S .
NATURE MEDICINE, 2002, 8 (01) :35-40
[3]   Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro [J].
Cao, Y ;
Zhao, ZF ;
Gruszczynska-Biegala, J ;
Zolkiewska, A .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (19) :6725-6738
[4]  
Carlson HA, 2000, MOL PHARMACOL, V57, P213
[5]   Hypertrophic cardiomyopathy [J].
Elliott, P ;
McKenna, WJ .
LANCET, 2004, 363 (9424) :1881-1891
[6]   Successful virtual screening for novel inhibitors of human carbonic anhydrase:: Strategy and experimental confirmation [J].
Grüneberg, S ;
Stubbs, MT ;
Klebe, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3588-3602
[7]   ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase [J].
Ito, N ;
Nomura, S ;
Iwase, A ;
Ito, T ;
Kikkawa, F ;
Tsujimoto, M ;
Ishiura, S ;
Mizutani, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 314 (04) :1008-1013
[8]   Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme [J].
Maskos, K ;
Fernandez-Catalan, C ;
Huber, R ;
Bourenkov, GP ;
Bartunik, H ;
Ellestad, GA ;
Reddy, P ;
Wolfson, MF ;
Rauch, CT ;
Castner, BJ ;
Davis, R ;
Clarke, HRG ;
Petersen, M ;
Fitzner, JN ;
Cerretti, DP ;
March, CJ ;
Paxton, RJ ;
Black, RA ;
Bode, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3408-3412
[9]   Cell-based assay for β-secretase activity [J].
Oh, M ;
Kim, SY ;
Oh, YS ;
Choi, DY ;
Sin, HJ ;
Jung, IM ;
Park, WJ .
ANALYTICAL BIOCHEMISTRY, 2003, 323 (01) :7-11
[10]   Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms [J].
Schaub, MC ;
Hefti, MA ;
Zuellig, RA ;
Morano, I .
CARDIOVASCULAR RESEARCH, 1998, 37 (02) :381-404